

Neuraminidase Inhibitors

I. Medications

- A. _____
- B. _____

II. Applications

- A. _____ & _____

III. Mechanism

- A. Inhibits _____ (_____)

IV. Adverse Effects

- A. Resistance

Amantadine & Rimantadine

I. Medications/Applications

- A. _____
 - 1. _____
 - 2. _____
- B. _____
 - 1. _____

II. Mechanism

- A. _____
 - 1. ↑ _____
 - 2. Blocks _____
- B. Disrupts _____
 - 1. Inhibits _____

III. Adverse Effects

- A. Restlessness
- B. Agitation
- C. Confusion

Adefovir

I. Application

- A. Hepatitis B

II. Mechanism

- A. _____
- B. _____ analog

III. Adverse Effects

- A. _____

Entecavir

I. Applications

- A. Hepatitis B

II. Mechanism

- A. Nucleoside analog
 - 1. Inhibits _____
 - 2. Inhibits _____
 - 3. Inhibits _____

III. Adverse Effects

- A. _____

Telbivudine

I. Applications

- A. Hepatitis B

II. Mechanism

- A. Thymidine analog
 - 1. Competes for _____

III. Adverse Effects

- A. _____

HCV Protease Inhibitors

I. Medications

- A. _____
- B. _____

II. Mechanism

- A. Inhibits _____

III. Applications

- A. _____
 - 1. Combined with ribavirin or interferon

IV. Adverse Effects

- A. Anemia
- B. Rapid resistance in monotherapy

Purine/Pyrimidine Analogs for Herpes Infections

I. Medications

- A. _____
 - 1. HSV 1&2, VZV, EBV
- B. _____
 - 1. _____ & prophylaxis
- C. _____
 - 1. HSV 1&2, VZV
- D. _____
 - 1. _____

E. Trifluridine

- 1. HSV keratoconjunctivitis

F. Valacyclovir

- 1. HSV 1&2, VZV

II. Mechanism

- 1. _____/_____ viral _____

III. Adverse Effects

- A. _____: Nephrotoxicity, neutropenia

Foscarnet

I. Applications

- A. _____
- B. Acyclovir resistant HSV

II. Mechanism

- A. _____

III. Adverse Effects

- A. Nephrotoxicity
- B. _____

Nucleoside & Nucleotide Reverse Transcriptase

Inhibitors

I. Medications

- A. _____
- B. _____
- C. _____
1. Hepatitis B
- D. _____
1. Hepatitis B
- E. _____
- F. _____
- G. _____

II. Applications

- A. _____

III. Mechanism

- A. Inhibits _____
1. Phosphorylated by cell enzymes, _____

Non-nucleoside Reverse Transcriptase Inhibitors

I. Medications

- A. _____
- B. _____
- C. _____
- D. _____

II. Applications

1. _____

III. Adverse Effects

- A. _____: TEN/Stevens-Johnson, Fatal hepatotoxicity
- B. _____

HIV Protease Inhibitors

I. Medications

- A. _____
- B. _____
- C. _____
- D. _____
- E. _____
- F. _____
- G. _____
- H. _____
- I. _____
- J. _____

II. Applications

- A. _____
- B. _____/_____: COVID-19

III. Mechanism

- A. Inhibits _____
1. _____ cleaves viral polypeptide into enzymes & proteins

IV. Adverse Effects

- A. _____, thinning of extremities
- B. Inhibits _____
- C. Resistance – mutations of _____

HIV Entry Inhibitors

I. Medications

- A. _____
- B. _____

II. Applications

- A. HIV

III. Mechanism

- A. _____, _____
- B. Enfuvirtide: _____
- C. Maraviroc: _____

IV. Adverse Effects

- A. _____: Alternate HIV gp41 coreceptor (CXCR4)

Integrase Inhibitors

I. Medications

- A. _____
- B. _____
- C. _____

II. Applications

- A. HIV

III. Mechanism

- A. Inhibits _____
1. Binds metal ions
2. Prevents _____

IV. Adverse Effects

- A. _____
1. Rhabdomyolysis
2. Suicidal ideation
- B. Resistance – mutations of _____